MLTX
MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology · CH
$15.01
−1.18%Aug 10, 2026, 11:00 UTC
MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints at Week 16, and reported second quarter 2026 financial results with $537.0 million in cash and cash equivalents as of the end of the quarter.
Source:Jun 24, 2026, 03:08 UTC
MoonLake Immunotherapeutics priced an upsized $200 million public offering of 9,000,000 Class A ordinary shares and pre-funded warrants for up to 1,000,000 Class A ordinary shares.
Source:Jun 1, 2026, 00:00 UTC
MoonLake Immunotherapeutics signed a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH for the manufacture of pre-filled application systems and capacity reservation.